(Q50770388)

English

Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1.

scientific article published on 18 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

attenuated vaccine

1 reference

based on heuristic

inferred from title

Ricardo Gazzinelli

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Luara Isabela Dos Santos

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Lis R Antonelli

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Santuza M R Teixeira

6

object named as

Santuza Maria Ribeiro Teixeira

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

8

object named as

Gerd Ritter

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Bruno Galvão-Filho

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Paula Cristina de Faria

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Caroline Junqueira

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Miriam Santos Dutra

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Maurício Martins Rodrigues

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Oliver Bannard

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Douglas Thomas Fearon

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

18 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

64

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

311-323

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25403749%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Improvement of different vaccine delivery systems for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Trypanosoma cruzi as an effective cancer antigen delivery vector.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

CD8+ T cells in Trypanosoma cruzi infection

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

The role of IFN-gamma Elispot assay in HIV vaccine research

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Molecular basis of non-virulence of Trypanosoma cruzi clone CL-14.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Cutting edge: rapid in vivo killing by memory CD8 T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Secondary replicative function of CD8+ T cells that had developed an effector phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Salmonella as live trojan horse for vaccine development and cancer gene therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Negative tissue parasitism in mice injected with a noninfective clone of Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

A fresh look at tumor immunosurveillance and immunotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Recruitment and endo-lysosomal activation of TLR9 in dendritic cells infected with Trypanosoma cruzi.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Requirement of UNC93B1 reveals a critical role for TLR7 in host resistance to primary infection with Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Lineage relationship and protective immunity of memory CD8 T cell subsets

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

CTLA-4 blockage increases resistance to infection with the intracellular protozoan Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Cancer immunotherapy shows promise in multiple tumor types

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1634-8

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50770388&oldid=2210492735"